前沿生物（688221）：小核酸领域的冉冉新星

Investment Rating - The report initiates coverage with a "Buy" rating for the company [11][13]. Core Insights - The company, Frontier Biotech, focuses on innovative drug development with a strong emphasis on technology and patent barriers, establishing a product portfolio that includes long-acting HIV drugs, new technology small nucleic acid drugs, and high-end generics [5][8]. - The company has developed a robust pipeline of small nucleic acid drugs targeting chronic diseases such as IgA nephropathy and dyslipidemia, with promising candidates FB7013 and FB7011 showing first-in-class (FIC) potential [9][31]. - The long-acting HIV drug, Aikening (ABT), has shown steady growth since its conditional approval in 2018 and received regular approval in 2023, with additional long-acting HIV products in development to strengthen the company's competitive position in the HIV treatment market [10][20]. Summary by Sections Company Overview - Frontier Biotech was established in 2013 and went public on the Shanghai Stock Exchange in 2020, focusing on unmet clinical needs in chronic disease treatment and building a dual-driven development model of innovative drugs and high-end generics [20][28]. Product Pipeline - The company has a diverse pipeline that includes long-acting HIV treatments and a variety of small nucleic acid drugs targeting diseases such as IgA nephropathy, high uric acid, and metabolic disorders [30][52]. - The small nucleic acid drugs are designed to regulate mRNA and have the potential to treat previously untreatable diseases, marking a significant advancement in drug development [31][35]. Financial Projections - Revenue forecasts for the company are projected at CNY 145 million, CNY 173 million, and CNY 210 million for the years 2025 to 2027, with net losses expected to decrease over the same period [11].